Company | Broadridge Financial Solutions, Inc. |
Ticker | BR (NYSE) |
Upcoming Earnings Date | August 4, 2026 (Tomorrow) |
Reporting Period | Q4 FY2026 (Quarter Ended June 30, 2026) |
Last Reported Quarter | Q3 FY2026 (Reported April 30, 2026) |
Preparation Date | August 3, 2026 |
Key Takeaway: Setup is modestly constructive — consensus is a manageable bar with low-to-mid single-digit adjusted EPS growth implied for Q4 — but the single biggest swing factor is whether closed sales show any sequential improvement after the guidance cut to $240–290M, which spooked investors last quarter.
Heading into Q4 FY2026 earnings, the bar for Broadridge is deliberately set low by management's own guidance: the Q3 call explicitly flagged low-to-mid single-digit adjusted EPS growth for Q4, reflecting elevated investment spending, a 5-point license revenue headwind in GTO Wealth, and only a partial offset from the CQG acquisition (contributing ~3 points to capital markets). Consensus adjusted EPS of $3.77 and total revenue of ~$2.16B are well-anchored to that guidance, making a clean beat achievable if position growth holds and event-driven revenue surprises to the upside. Management raised full-year recurring revenue guidance to “at or above 7%” and adjusted EPS to 10–12% at Q3, and has since reiterated confidence at the Needham, Bernstein, and RBC conferences — tone has been consistently constructive with no negative pre-announcements. Estimate revisions have been stable-to-slightly-positive since the Q3 print, with the full-year EPS consensus of ~$9.56 essentially unchanged from the post-Q3 baseline, suggesting the street has fully digested the closed sales cut and is not pricing in further deterioration. The stock has underperformed the S&P 500 materially since last earnings (BR ~+2% vs. SPY ~+5% through August 3), trading near the low end of its historical P/E range and offering a compelling entry if management can demonstrate that the closed sales pipeline is converting — the wildcard is whether Q4 closed sales ($135M consensus) show any acceleration, which would be the clearest signal that the elongated deal cycle narrative is timing, not demand.
Key Takeaway: Consensus is a low bar for Q4 — management pre-guided to low-to-mid single-digit EPS growth and the street is aligned. Recurring fee revenue is the bigger swing factor given the proxy season visibility management cited (93% of proxies received), while closed sales is the key sentiment driver regardless of the financial beat/miss.
KPI | Q3 FY2026 Actual | Q4 FY2025 Actual (Prior Year) | Q4 FY2026 Consensus Estimate | YoY Change | Guidance | Consensus vs. Guidance |
Total Revenue ($M) | $1,953.6M | $2,065.4M | $2,164.1M | +4.8% YoY | At or above 7% recurring rev growth (FY) | N/A (total rev not guided directly) |
Recurring Fee Revenue ($M) | $1,288.1M | $1,423.6M | $1,506.7M | +5.8% YoY | At or above 7% CC growth (FY) | Tracking to guidance |
Adjusted EPS (Operating) | $2.72 | $3.55 | $3.77 | +6.2% YoY | Low-to-mid single-digit Q4 growth (implied) | ~+6% vs. low-mid single-digit — at high end |
Event-Driven Revenue — ICS ($M) | $72.7M | $78.9M | $69.0M | -12.5% YoY | No specific Q4 guidance | N/A |
GTO Revenue ($M) | $488.3M | $464.7M | $483.6M | +4.1% YoY | +3pt CQG contribution; -5pt license headwind in Wealth | Tracking to guidance |
ICS Revenue ($M) | $1,465.1M | $1,600.7M | $1,679.0M | +4.9% YoY | High single-digit regulatory rev growth; low double-digit equity positions | Tracking to guidance |
Closed Sales ($M) | $57.5M | $113.5M | $135.4M | +19.3% YoY | $240–290M FY2026 (implies ~$72–122M in Q4) | $135M consensus is above midpoint of implied Q4 range |
Equity Record Growth (%) | 15% | 18% | ~5% (consensus) | Deceleration YoY | Low double-digit equity revenue positions | Consensus below management guidance |
Mutual Fund Record Growth (%) | 6% | 7% | ~6% (consensus) | Roughly flat YoY | Mid-to-high single-digit fund position growth | Consensus at low end of guidance |
Sources: Visible Alpha Consensus and Actuals Data. All VA-sourced figures cited per dataset.
Top KPI #1: Recurring Fee Revenue ($M)
Quarter | Reported ($M) | Consensus ($M) | Surprise % | Result |
Q4 FY2024 | $1,326.4M | $1,331.8M | -0.4% | Miss |
Q1 FY2025 | $900.3M | $904.8M | -0.5% | Miss |
Q2 FY2025 | $980.2M | $955.7M | +2.6% | Beat |
Q3 FY2025 | $1,203.9M | $1,229.7M | -2.1% | Miss |
Q4 FY2025 | $1,423.6M | $1,430.8M | -0.5% | Miss |
Q1 FY2026 | $977.5M | $967.4M | +1.0% | Beat |
Q2 FY2026 | $1,070.1M | $1,042.1M | +2.7% | Beat |
Q3 FY2026 | $1,288.1M | $1,261.5M | +2.1% | Beat |
Top KPI #2: Adjusted EPS — Operating ($)
Quarter | Reported ($) | Consensus ($) | Surprise % | Result |
Q4 FY2024 | $3.50 | $3.50 | 0.0% | In-Line |
Q1 FY2025 | $1.00 | $0.99 | +1.0% | Beat |
Q2 FY2025 | $1.56 | $1.49 | +4.7% | Beat |
Q3 FY2025 | $2.44 | $2.42 | +0.8% | Beat |
Q4 FY2025 | $3.55 | $3.50 | +1.4% | Beat |
Q1 FY2026 | $1.51 | $1.25 | +20.8% | Beat |
Q2 FY2026 | $1.59 | $1.37 | +16.1% | Beat |
Q3 FY2026 | $2.72 | $2.59 | +5.0% | Beat |
Pattern: BR has beaten adjusted EPS consensus in 7 of the last 8 quarters, with particularly large beats in Q1 and Q2 FY2026 (+20.8% and +16.1% respectively). Recurring fee revenue has been more mixed — 3 beats and 5 misses/in-lines over the same period — suggesting the EPS beat cadence is partly driven by cost discipline and below-the-line items rather than pure top-line outperformance. Source: Visible Alpha Consensus and Actuals Data.
Key Takeaway: Guidance has been raised twice since the start of FY2026 on both recurring revenue and EPS, and management has reiterated the full-year outlook at every conference since Q3 earnings — no negative pre-announcements. The one negative shift — the closed sales guidance cut to $240–290M from $290–330M — was disclosed at Q3 and is fully in the numbers.
Metric | Initial Guidance (Q3 FY2026 Earnings Call, Apr 30, 2026) | Revised Guidance | Current Consensus | Note |
Recurring Revenue Growth (CC) | At or above 7% | — | ~7%+ (FY2026 implied) | Reiterated at Needham (May 12), Bernstein (May 27), RBC (Jun 9). No change. |
Adjusted EPS Growth (FY2026) | 10–12% | — | ~10–12% (FY2026 consensus $9.56) | Reiterated at all three post-Q3 conferences. Implies low-to-mid single-digit Q4 EPS growth. |
Q4 Adjusted EPS Growth (implied) | Low-to-mid single-digit | — | $3.77 (+6.2% YoY) | Reflects elevated Q4 investment spending. Consensus at high end of implied range. |
AOI Margin (FY2026) | ~20–21% | — | ~20–21% | Unchanged. Similar Q4 margin dynamic to Q3 expected. |
Closed Sales (FY2026) | $240–290M (cut from $290–330M at Q3) | — | $282M FY2026 consensus | ↓ Cut at Q3 earnings (Apr 30). Elongated deal cycles on larger GTO/ICS deals. Pipeline at record >$1B. Impact to recurring rev: 10–30 bps over 12–18 months. |
Q4 Equity Revenue Position Growth | Low double-digit | — | ~5% (consensus) | Management has 93% of proxies received — high confidence. Consensus appears conservative vs. guidance. |
Q4 Fund Position Growth | Mid-to-high single-digit | — | ~6% (consensus) | Consensus at low end of guidance range. |
Free Cash Flow (FY2026) | >$1.1B (>100% conversion) | — | N/A — not in VA | Management flagged ample capacity for M&A and buybacks in Q4. |
Key Takeaway: Estimates have been remarkably stable since the Q3 print — the street has fully absorbed the closed sales cut and is not pricing in further deterioration. FY2026 EPS consensus of $9.56 is essentially unchanged from the post-Q3 baseline of $9.55, and FY2027 estimates are also stable, suggesting the market views the closed sales miss as a timing issue, not a structural demand problem.
KPI (Period) | Estimate ~5 Days Post Q3 Earnings (May 5, 2026) | Current Consensus | Estimate Δ (%) | Initial Guidance (Q3 Call) | Current Guidance | Guidance Δ | Consensus vs. Guidance (%) |
Recurring Fee Revenue — Q4 FY2026 | $1,507.0M | $1,506.7M | ~0.0% | At or above 7% CC (FY) | Unchanged | — | Tracking to guidance |
Recurring Fee Revenue — FY2026 | $4,842.6M | $4,842.3M | ~0.0% | At or above 7% CC | Unchanged | — | Tracking to guidance |
Recurring Fee Revenue — FY2027 | $5,156.3M | $5,149.9M | -0.1% | N/A (next cycle) | N/A | — | N/A |
Adjusted EPS — Q4 FY2026 | $3.75 | $3.77 | +0.5% | Low-to-mid single-digit growth (implied) | Unchanged | — | At high end of implied range |
Adjusted EPS — FY2026 | $9.55 | $9.56 | +0.1% | 10–12% growth | Unchanged | — | Tracking to guidance midpoint |
Adjusted EPS — FY2027 | $10.37 | $10.41 | +0.4% | N/A (next cycle) | N/A | — | N/A |
Closed Sales — FY2026 | $282.2M | $282.2M | 0.0% | $240–290M | Unchanged | — | Consensus at midpoint of guidance range |
Estimates have been essentially frozen since the Q3 print — the largest move is +0.5% on Q4 EPS, which is noise. This stability is a double-edged sword: it confirms the street has digested the closed sales cut, but it also means there is no estimate cushion built in from downward revisions. The risk/reward is asymmetric to the upside if Q4 closed sales surprise. Source: Visible Alpha Consensus and Actuals Data.
Key Takeaway: BR has significantly underperformed the S&P 500 since Q3 earnings (Apr 30, 2026), declining ~-0.4% vs. SPY +5.4% through August 3 — driven by multiple compression rather than estimate cuts, as EPS revisions have been flat. The stock hit a trough of ~$135 in late June before recovering to ~$154, suggesting the market is beginning to re-rate the closed sales narrative as timing rather than structural.
BR vs. S&P 500 (SPY) — Indexed to 100 at Last Earnings Date (Apr 30, 2026). Source: Stock Price Data.
Key observations: (1) BR sold off sharply in mid-May (to ~$143) as the market digested the closed sales guidance cut and sector rotation toward hyperscalers continued; (2) the stock bottomed in late June (~$135–136) before recovering on improving sentiment around the pipeline narrative and broader fintech re-rating; (3) the S&P 500 has outperformed throughout, reflecting BR’s idiosyncratic headwinds rather than macro. The stock currently trades at approximately 21x NTM EPS — below its 5-year average of ~25x — offering a valuation entry point if Q4 execution is clean. Sector ETF used: SPY (S&P 500), as BR’s closest liquid benchmark given its diversified fintech/infrastructure profile. Source: Stock Price Data.
Key Takeaway: The most important development since Q3 earnings is the launch of agentic AI in production (May 11, 2026) and the comprehensive tokenized equities governance solution (May 5, 2026) — both validate the strategic narrative management has been building and could drive incremental pipeline conversion in FY2027.
Key Takeaway: Peer commentary since Q3 earnings (April 30, 2026) is broadly constructive for BR’s Q4 setup — financial institution technology budgets are at record levels, capital markets ACV is accelerating, and digital/AI demand is robust. The one watch item is elongated deal cycles for larger, complex engagements, which Jack Henry and FIS both corroborated, validating BR’s closed sales narrative as an industry-wide dynamic rather than a company-specific problem.
Note: Only commentary from the last 60 days (since ~June 3, 2026) or post-Q3 earnings conferences that speak to the current quarter (Q4 FY2026, ending June 30, 2026) or forward demand environment is included. Prior-quarter earnings results from peers are excluded.
Relevance to BR: FIS serves the same financial institution client base as BR’s GTO segment and competes in capital markets technology. FIS commentary on banking technology budgets, capital markets ACV, and AI adoption is a direct read-through to BR’s GTO pipeline and deal cycle dynamics.
Relevance to BR: JKHY serves community banks and credit unions — a key client segment for BR’s GTO wealth management platform. JKHY’s commentary on bank technology budgets, deal cycles, and digital transformation is a direct read-through to BR’s GTO wealth pipeline.
Relevance to BR: State Street is a major custodian bank and one of BR’s largest ICS clients (proxy/disclosure, fund communications). STT’s commentary on AUC growth, fund flows, digital assets, and technology investment is a direct read-through to BR’s ICS recurring revenue and position growth.
Relevance to BR: Fiserv serves financial institutions with payments and banking technology — overlapping with BR’s GTO wealth management client base. FI’s commentary on bank technology spending, deal cycles, and digital transformation is a secondary read-through.
Peer | Event / Date | Key Signal | Read-Through for BR | Direction |
FIS | Q1 Earnings, May 8 | Capital markets ACV +45% YoY; banking budgets at record levels | Positive for GTO capital markets pipeline and deal conversion | Positive |
FIS | Mizuho Conference, Jun 9 | Banking at “generational moment”; M&A at record levels; AI spend quadrupling | Positive for ICS position growth (M&A) and GTO AI managed service opportunity | Positive |
JKHY | Q3 Earnings, May 6 | 88% of banks increasing tech budgets; deal cycles longer for larger deals | Validates BR closed sales timing narrative; positive for GTO wealth pipeline | Mixed |
JKHY | RBC Conference, Jun 9 | Pipeline at highest level in recent years; 60% of wins are trifecta (core+digital+card) | Positive for BR GTO wealth platform pipeline conversion | Positive |
STT | Q2 Earnings, Jul 16 | AUC record $57.9T (+18%); fee revenue guidance raised to 12–13% | Positive for ICS fund/equity position growth and event-driven revenue | Positive |
STT | Q2 Earnings, Jul 16 | Tokenized fund servicing announced; stablecoin reserves fund launched | Validates BR tokenized equities governance opportunity; STT likely early client | Positive |
FI | Q1 Earnings, May 5 | Stablecoin pilot summer 2026; Project Keystone tokenized deposits with 5 banks | Validates digital asset infrastructure buildout; positive for BR’s tokenization TAM | Positive |
Key Takeaway: No open-market buys or discretionary sells by executives since Q3 earnings. The only notable transaction is a single open-market sale by Chief Legal Officer Hope Jarkowski (June 4, 2026) — a small, likely tax-driven disposition. Director equity awards in June and July are routine compensation grants, not market signals. Overall, the insider picture is neutral — no clustered buys or unusual sale activity.
Name | Title | Transaction Type | Shares | Date | Note |
Jarkowski, Hope M. | Chief Legal Officer | Open Market Sale | 1,966 shares | Jun 4, 2026 | Discretionary sale; left 1.25 shares remaining — likely tax withholding or estate planning. Small size, not a signal. |
Ghei, Ashima | CFO | RSU Vesting (M) + Tax Withholding (F) | 2,509 vested; 905 withheld for taxes | Jun 27, 2026 | FY2024 RSU grant vesting. Tax withholding sale (code F) is obligation-driven, not discretionary. Net 1,604 shares acquired. |
Markus, Maura A. | Director | Director Equity Award (A) | 239 shares (Jun 10); 134 shares (Jul 2) | Jun 10 & Jul 2, 2026 | Routine director compensation grants. Not open-market purchases. |
Murray, Eileen K. | Director | Director Equity Award (A) | 445 shares (Jun 10); 38 shares (Jul 2) | Jun 10 & Jul 2, 2026 | Routine director compensation grants. Not open-market purchases. |
Nazareth, Annette L. | Director | Director Equity Award (A) | 206 shares (Jun 10); 39 shares (Jul 2) | Jun 10 & Jul 2, 2026 | Routine director compensation grants. Not open-market purchases. |
Zavery, Amit | Director | Director Equity Award (A) | 206 shares (Jun 10); 60 shares (Jul 2) | Jun 10 & Jul 2, 2026 | Routine director compensation grants. Not open-market purchases. |
Mosconi, Patricia Ann | Director | Director Equity Award (A) | 206 shares (Jun 10); 3 shares (Jul 2) | Jun 10 & Jul 2, 2026 | Routine director compensation grants. Not open-market purchases. |
Duelks, Robert N. | Director | Director Equity Award (A) | 143 shares (Jul 2) | Jul 2, 2026 | Routine director compensation grant. Not open-market purchase. |
Flowers, Melvin L. | Director | Director Equity Award (A) | 18 shares (Jul 2) | Jul 2, 2026 | Routine director compensation grant. Not open-market purchase. |
Source: Insider Transaction Data (SEC Form 4 filings). Open-market transactions only (codes P/S) plus RSU vesting events. All director equity awards (code A) are routine compensation grants and are not open-market purchases. The CFO’s tax withholding sale (code F) is obligation-driven. No clustered open-market buys or unusual discretionary sales were identified in the period since Q3 earnings (April 30, 2026).
— End of Report —